Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®GlobeNewsWire • 02/03/23
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed ReportInvestors Business Daily • 02/01/23
Novartis posts lower sales and profit on generic competition, but boosts 2022 dividendMarket Watch • 02/01/23
Novartis continues to grow with further core margin expansion and achieves important innovation milestonesGlobeNewsWire • 02/01/23
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5GlobeNewsWire • 12/13/22
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNHGlobeNewsWire • 12/08/22